JP2023540212A - ヒト卵黄嚢様造血細胞を生成するための組成物および方法 - Google Patents

ヒト卵黄嚢様造血細胞を生成するための組成物および方法 Download PDF

Info

Publication number
JP2023540212A
JP2023540212A JP2023513088A JP2023513088A JP2023540212A JP 2023540212 A JP2023540212 A JP 2023540212A JP 2023513088 A JP2023513088 A JP 2023513088A JP 2023513088 A JP2023513088 A JP 2023513088A JP 2023540212 A JP2023540212 A JP 2023540212A
Authority
JP
Japan
Prior art keywords
cells
composition
cell
optionally
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513088A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022040798A5 (https=
JP2023540212A5 (https=
Inventor
ケラー，ゴードン
アトキンス，マイケル
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2023540212A publication Critical patent/JP2023540212A/ja
Publication of JPWO2022040798A5 publication Critical patent/JPWO2022040798A5/ja
Publication of JP2023540212A5 publication Critical patent/JP2023540212A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023513088A 2020-08-25 2021-08-25 ヒト卵黄嚢様造血細胞を生成するための組成物および方法 Pending JP2023540212A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069904P 2020-08-25 2020-08-25
US63/069,904 2020-08-25
PCT/CA2021/051181 WO2022040798A1 (en) 2020-08-25 2021-08-25 Compositions and methods for generating human yolk sac-like hematopoietic cells

Publications (3)

Publication Number Publication Date
JP2023540212A true JP2023540212A (ja) 2023-09-22
JPWO2022040798A5 JPWO2022040798A5 (https=) 2024-08-30
JP2023540212A5 JP2023540212A5 (https=) 2024-08-30

Family

ID=80354070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513088A Pending JP2023540212A (ja) 2020-08-25 2021-08-25 ヒト卵黄嚢様造血細胞を生成するための組成物および方法

Country Status (5)

Country Link
US (1) US20230374458A1 (https=)
EP (1) EP4204544A4 (https=)
JP (1) JP2023540212A (https=)
CA (1) CA3190402A1 (https=)
WO (1) WO2022040798A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202022002866U1 (de) 2021-04-01 2024-03-20 The Regents Of The University Of California Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
US20260108560A1 (en) * 2022-07-13 2026-04-23 The Regents Of The University Of California Transplanting stem cell-derived microglia to treat leukodystrophies
WO2024107010A1 (ko) * 2022-11-17 2024-05-23 주식회사 씨티셀즈 미분화 줄기세포로부터 자연 살해 세포로의 분화 방법 및 이의 용도
AU2023415203A1 (en) * 2022-12-28 2025-08-07 National University Corporation Chiba University Method for regulating degree of cell differentiation
WO2024216379A1 (en) * 2023-04-18 2024-10-24 University Health Network Use of macrophages for improved pancreatic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512031A (ja) * 2013-03-13 2016-04-25 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031404A1 (en) * 2016-08-10 2018-02-15 Indiana University Research And Technology Corporation Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512031A (ja) * 2013-03-13 2016-04-25 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DITADI, A. ET AL.: "Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineage", NATURE CELL BIOLOGY, vol. 17, no. 5, JPN6025041209, 2015, pages 580 - 591, ISSN: 0005703090 *
STURGEON, C. M. ET AL.: "Wnt Signaling Controls the Specification of Definitive and Primitive Hematopoiesis from Human Plurip", NAT BIOTECHNOL, vol. 32, no. 6, JPN6025041208, 2014, pages 554 - 561, ISSN: 0005703091 *

Also Published As

Publication number Publication date
US20230374458A1 (en) 2023-11-23
WO2022040798A1 (en) 2022-03-03
EP4204544A4 (en) 2024-10-30
EP4204544A1 (en) 2023-07-05
CA3190402A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
Ratajczak et al. Adult murine bone marrow-derived very small embryonic-like stem cells differentiate into the hematopoietic lineage after coculture over OP9 stromal cells
JP2023540212A (ja) ヒト卵黄嚢様造血細胞を生成するための組成物および方法
JP2024026891A (ja) 造血系統細胞を製造するための方法およびシステム
US20250333701A1 (en) Compositions and methods for generating hematopoietic stem cells (hscs)
US20130064801A1 (en) Cellular Compositions and Methods of Making and Using Them
JP2010042011A (ja) ヒト胚性幹細胞の造血分化
JP7522800B2 (ja) 造血移植片の改善方法
Tamaoki et al. Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells
AU2012298997B2 (en) Angiohematopoietic progenitor cells
Martin‐Rendon et al. Exploitation of stem cell plasticity
Niwa et al. Orderly hematopoietic development of induced pluripotent stem cells via Flk‐1+ hemoangiogenic progenitors
Wang et al. Hypoxia drives hematopoiesis with the enhancement of T lineage through eliciting arterial specification of hematopoietic endothelial progenitors from hESC
EP4352208A1 (en) A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof
Kanji et al. Plasticity and maintenance of hematopoietic stem cells during development
US20080171384A1 (en) Method of obtaining a population of human haemopoietic stem cells
Li et al. Modulation of WNT, activin/nodal, and MAPK signaling pathways increases arterial hemogenic endothelium and hematopoietic stem/progenitor cell formation during human iPSC differentiation
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
Guyonneau-Harmand et al. Transgene-free hematopoietic stem and progenitor cells from human induced pluripotent stem cells
Kang Generation of HIV-1 resistant, functional blood cells from human pluripotent stem cells for the stem cell-based therapy
WO2023247722A1 (en) Method for isolating hemogenic endothelial cells
Flosdorf The impact of the JAK2 V617F mutation on megakaryocytes and bone marrow fibrosis in an iPS cell model
Collins Functional Interrogation of JAK2 and ASXL1 Mutations in Myeloproliferative Neoplasms
Creamer The role of CDX4 during patterning of definitive hemogenic mesoderm
JP2025534356A (ja) 細胞療法のためのｃｄ７１＋赤血球前駆細胞の拡張可能な拡大培養
O'Brien Induced Human Pluripotent Stem Cell–derived NK Cells as an Alternative Source of Lymphocytes for Anti-Cancer Immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309